Global Influenza Vaccine Market Size, Share, and COVID-19 Impact Analysis, By Vaccine Type (Inactivated and Live Attenuated), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Influenza Vaccine Market Insights Forecasts to 2035

• The Global Influenza Vaccine Market Size Was Estimated at USD 8.52 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 7.30% from 2025 to 2035
• The Worldwide Influenza Vaccine Market Size is Expected to Reach USD 18.50 Billion by 2035
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global Influenza Vaccine Market Size was Worth around USD 8.52 Billion in 2024 and is predicted to Grow to around USD 18.50 Billion by 2035 with a Compound Annual Growth Rate (CAGR) of 7.30% from 2025 and 2035. The primary factors driving the influenza vaccine market are the increasing prevalence of influenza, the growing recommendations for vaccination, the growing public awareness of the need for vaccination against life-threatening illnesses, and the improvement of national immunization programs.    

Market Overview

The global industry centered on the creation, manufacturing, marketing, and distribution of vaccines intended to ward against influenza viruses is known as the influenza vaccine market. It includes a variety of vaccination forms, such as recombinant, live attenuated, and inactivated vaccines. The goal of the influenza vaccine market is to prevent an epidemic of influenza using government immunization programs, technical advancements, effective distribution channels, and advanced vaccine development. For Instance, in February 2025, the World Health Organization (WHO) announced guidelines for the viral composition of influenza vaccinations for the northern hemisphere influenza season of 2025–2026.  

One of the factors driving the market's growth is the increase in surveillance and government assistance for vaccination at the national and international levels to track the administration, distribution, and supply of vaccines.  The introduction of numerous beneficial government initiatives to encourage vaccination programs, rising influenza incidence and seasonal outbreaks, and more potent and widely protective influenza vaccinations are some of the primary factors driving the growth of the influenza vaccine market. 

Report Coverage

This research report categorizes the influenza vaccine market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the influenza vaccine market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the influenza vaccine market. 

Driving Factors

Technological developments in the products and their production process, along with possible pipeline candidates and growing focus on vaccination programs in developing economies to help in vaccine acceptance, are expected to propel the influenza vaccine market. Adoption of the product is expected to be driven by more knowledge of the advantages of vaccination, vaccination coverage, and the availability of potent vaccinations on the market.  

The development of an effective vaccine against a specific strain presents pharmaceutical companies with ongoing problems. Consequently, the market is expected to be driven by the growing need for the influenza vaccine. The increasing incidence of influenza, especially in susceptible groups like the elderly, increases demand even more. Moreover, mass immunization campaigns and government initiatives facilitate the broad dissemination of vaccines, which fuels influenza vaccine market expansion.  

Restraining Factors

Growth in the market is expected to be restricted by the lengthier time needed to complete clinical trials and the stricter regulatory requirements. The market's expansion can also be restricted by elements including stability, the organism's natural biological characteristics, and the absence of a standard production template for vaccinations.

Market Segmentation

The influenza vaccine market share is classified into vaccine type and distribution channel.   

• The inactivated segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the vaccine type, the influenza vaccine market is divided into inactivated and live attenuated. Among these, the inactivated segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. Inactivated vaccines are made of bacteria, viruses, and other pathogens that have been cultured and subsequently killed to eliminate their ability to cause disease. Children aged 6 to 35 months received the inactivated vaccine had an effective antibody response even a year after the first dose, and it later decreased the risk of contracting influenza A and B.  

• The hospital & retail pharmacies segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the distribution channel, the influenza vaccine market is divided into hospital & retail pharmacies, government suppliers, and others. Among these, the hospital & retail pharmacies segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The theory for the hospital and retail pharmacy category is that vaccinations are typically administered in smaller facilities and are generally favored. Furthermore, a significant market value is anticipated in the next years due to the substantial vaccination supply from hospitals.   

Regional Segment Analysis of the Influenza Vaccine Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the influenza vaccine market over the predicted timeframe.

North America is anticipated to hold the largest share of the influenza vaccine market over the predicted timeframe. North America's rapid introduction of successful medicines and the region's highly developed vaccine manufacturing capabilities are to blame. It is anticipated that the region's market would expand due to the quick introduction of successful products and the presence of highly developed vaccine production facilities throughout the region. Regional growth is also anticipated to be fueled by rising influenza vaccine sales and the rising prevalence of influenza infection in the United States and Canada.

Asia Pacific is expected to grow at a rapid CAGR in the influenza vaccine market during the forecast period. Growing senior populations, better healthcare infrastructure, and the entry of new competitors are all factors driving market expansion in the Asia Pacific region. The region's market is expected to develop as a result of the growing number of government activities to distribute these vaccines and raise awareness about influenza. Additionally, the growing populations in China and India, as well as the increased need for vaccines that work and result in higher sales, are anticipated to propel market expansion.

Middle East & Africa is predicted to hold a significant share of the influenza vaccine market throughout the estimated period. The introduction of the influenza vaccine, increased government attempts to vaccinate everyone, and growing awareness of the influenza virus are all factors contributing to the market's expansion throughout the Middle East and Africa. The primary drivers of the industry are expanding government programs, international aid, and rising awareness of preventative healthcare.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the influenza vaccine market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Abbott
• GSK plc
• Sanofi
• CSL Limited
• EMERGENT
• Pfizer Inc
• Viatris Inc.
• AstraZeneca
• OSIVAX
• SINOVAC
• Merck & Co., Inc.
• GlaxoSmithKline plc
• EMERGEX VACCINES
• Vaxess Technologies Inc
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In February 2025, Zydus Lifesciences announced the launch of a vaccine designed to defend against a novel strain of the influenza virus. According to a statement from the Ahmedabad-based pharmaceutical giant, the business is launching the nation's first flu protection quadrivalent influenza virus vaccine, by WHO recommendations.

• In January 2025, Moderna, Inc. announced that the U.S. Department of Health and Human Services (HHS) is continuing to support the company's efforts to produce pandemic influenza vaccines based on mRNA. The Biomedical Advanced Research and Development Authority (BARDA), a division of the HHS Administration for Strategic Preparedness and Response (ASPR), provided funds for the Swift Response Partnership Vehicle (RRPV) Consortium, which made the grant. 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the influenza vaccine market based on the below-mentioned segments: 

Global Influenza Vaccine Market, By Vaccine Type  

• Inactivated
• Live Attenuated

Global Influenza Vaccine Market, By Distribution Channel  

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

Global Influenza Vaccine Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa